Fig. 1
From: SLAMF7 modulates B cells and adaptive immunity to regulate susceptibility to CNS autoimmunity
SLAMF7 displays unique expression patterns in the CNS and protects from EAE. A Clinical scores of WT (n = 14) and SLAMF7−/− mice (n = 16) subjected to EAE induced with rmMOG1–125. B Change in baseline weight for mice in A. C Clinical scores of WT (n = 8) and SLAMF7−/− mice (n = 8) subjected to EAE induced with rhMOG35–55. D UMAP of the entire CNS immune landscape in WT and SLAMF7−/− mice subjected to EAE with rmMOG1–125. The complete CNS immune landscape was assessed via high-dimensional single-cell spectral cytometry. E Marker expression on CNS immune cell subsets from D. F Scaled SLAMF7 expression plotted on the UMAP projection of all CNS immune cells from D. G Density plots of SLAMF7 expression across CNS immune subsets from D. H Histograms of SLAMF7 expression on CNS immune cell subsets at steady state and during active EAE (with rmMOG1–125) neuroinflammation. I SLAMF7 expression on all CNS immune cells at steady state and during EAE (with rmMOG1–125). Groups in A compared with a two-way ANOVA with Sidak’s multiple comparison test, displayed with mean ± SEM, and representative of two independent experiments showing similar results. Groups in B compared with a two-way ANOVA with Fisher’s LSD test. Groups in C compared with a mixed-effects model with Sidak’s multiple comparison test, displayed with mean ± SEM, and representative of a single experiment. Groups in I compared with an unpaired two-way t-test and representative of two independent experiments showing similar results. *p < 0.05, **p < 0.01. BAMS, border-associated macrophages; MdCs, myeloid-derived cells; AF, autofluorescence